Acromegaly Clinical Trial
Official title:
Descriptive Study of Buccodental Manifestations in a Group of Acromegalic Patients (AcroDent) Followed in the Endocrinology/Diabetology Service in the CHU of Clermont-Ferrand
Context: Acromegaly is the rare condition (3 to 4 new cases per million per year) due to
Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin
Growth Factor 1 (IGF-1) excess. Consequently, many tissues of the organism become
hypertrophied. Hypertrophy of gingival and dental tissues can lead to alteration of oral
health. However, there are very few published data concerning oral impact of acromegaly.
Objective: To do the most accurate clinical and radiological state of oral manifestations in
the series of prevalent acromegaly patients followed in the endocrinology service of the CHU
of Clermont-Ferrand.
Context/ study relevance: Acromegaly is a rare condition (3 to 4 new cases per million per
year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting
in Insulin Growth Factor 1 (IGF-1) excess. Consequently, a dysmorphic syndrome prevailing at
the level of face and extremities progressively develops associated with potentially severe
general manifestations (cardiovascular, respiratory and metabolic complications). Oral
manifestations of acromegaly are not well known, there is very few published data on this
topic and a controversy about the existence of a parodontal disease, i.e. the presence of
gingival sulcus deepening which can lead to tooth loss. IGF-1 excess could lead to gingival
hypertrophy and then to gingival sulcus deepening. Otherwise, the dental cementum, the only
dental tissue which can grow during all lifetime, could be influenced by an excess of IGF-1.
It is likely that acromegaly is associated with pathological cementum hypertrophy.
Objective: To do the most accurate clinical and radiological state of oral manifestations in
the series of prevalent acromegaly patients followed in the endocrinology service of the CHU
of Clermont-Ferrand. Investigator will take a special interest in parodontal status i.e. the
state of supporting tissues of the teeth and structural anomalies of dental cementum.
As secondary objective, investigator would make a histological characterization of gingival
and dental (cementum) tissues when a surgical treatment of the oral condition is required.
Investigator will search hypertrophic anomalies linked with GH/IGF-1 excess.
Material and methods: This is an observational, descriptive, cross-sectional, monocentric
study conducted in the endocrinology/diabetology service of Clermont-Ferrand University
Hospital (CHU), in France, where a series of about 70 prevalent acromegaly patients is
annually followed. The participants will be adult acromegaly patients followed in this
service, with proven diagnosis of acromegaly or previous acromegaly. They will be excluded of
the study if they are totally toothless, if they take a medication associated with gingival
hypertrophy if they are in a medical or chirurgical condition interacting with oral health so
that the oral evaluation is not reliable or if there is no possibility of written informed
consent. For each participant, investigator will collect demographic data and history of the
pathology including previous and actual complications, biological tests results, imaging
exams results and treatments. The participants will answer 3 questionnaires: AcroQol (quality
of life in acromegaly patients), GOHAI (General Oral Health Assessment Index) and EPICES
(evaluation of precariousness). The primary outcome will be a quantitative assessment of the
oral health of the acromegalic patients with detailed assessment of 3 criteria:
- Depth of gingival sulcus measured for of all teeth
- CAO index (number of teeth with cavity or obturation or missing)
- Thickness of dental cementum on orthopantomogram and all other abnormality on this exam.
The secondary outcome will be the histological analysis of gingival and dental tissues if
available.
All these measures will be taken during a routine odonto-stomatological consultation, part of
the annual pathology evaluation at the endocrinology/diabetology service.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06344650 -
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
|
||
Active, not recruiting |
NCT02092129 -
Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
|
N/A | |
Completed |
NCT02012127 -
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
|
||
Active, not recruiting |
NCT01265121 -
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
|
N/A | |
Terminated |
NCT00765323 -
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
|
Phase 3 | |
Completed |
NCT00500227 -
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
|
||
Completed |
NCT00531908 -
Physiopathology of Sodium Retention in Acromegaly
|
N/A | |
Completed |
NCT01278342 -
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
|
Phase 4 | |
Active, not recruiting |
NCT01809808 -
A Prospective Study of Outcome After Therapy for Acromegaly
|
||
Completed |
NCT00145405 -
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
Phase 4 | |
Completed |
NCT00210457 -
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
Phase 3 | |
Recruiting |
NCT05401084 -
Diet in the Management of Acromegaly
|
N/A | |
Recruiting |
NCT00005100 -
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|
N/A | |
Completed |
NCT00521300 -
Preoperative Octreotide Treatment of Acromegaly
|
Phase 4 | |
Completed |
NCT03548415 -
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
|
Phase 2 | |
Not yet recruiting |
NCT04066569 -
Reproducibility and Utility of OGTT in Acromegaly
|
N/A | |
Not yet recruiting |
NCT05298891 -
Hypoproteic Diet in Acromegaly
|
N/A | |
Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
Active, not recruiting |
NCT03252353 -
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
|
Phase 3 |